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self-antigens may provide important targets for 
cancer vaccines.
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Background:
SCIB1 is a DNA vaccine encoding a human IgG1 
antibody with CDRs that contain four epitopes 
from two melanoma antigens (three from gp100 
and one from TRP2). The vaccine elicits potent 
anti-tumour responses by stimulating high 
frequency, high avidity T-cells via both direct and 
cross-presentation of antibody. A clinical study in 
stage III/IV melanoma patients, all with tumour 
present at study entry, showed that 2-8mg doses 
could induce T-cell responses in 7/9 patients 
with no associated toxicity. Encouragingly overall 
survival was 31 months. This study addresses 
the question as to whether SCIB1 can be 
used as an adjuvant therapy in fully resected 
melanoma patients to prevent further disease.
Methods: 
Sixteen patients with fully resected stage 
III (n=9) or stage IV (n=7) melanoma were 
immunised with 4mg of SCIB1 by intramuscular 
electroporation at 3 weekly intervals and 
subsequently at 3 and 6 months.  Patients could 
continue treatment for 5 years.
Results:
All 16 patients showed vaccine-epitope-specific 
T-cell responses (i.e. proliferation ex vivo and/
or γIFN Elispot responses in-vitro). Twelve 
patients responded to all four epitopes, two 
patients to three epitopes, one to two epitopes 
and one to a single epitope. Five patients remain 
in the continuation phase - all show strong 
T-cell memory responses following boosting. 
At present, median survival time is 37 months 
from trial entry and 41.5 months from diagnosis 
of metastases. Overall survival is 100% for 
both groups. Five patients relapsed at 1, 4, 14, 
17 and 18 months but have shown no further 
recurrences at follow-up.
Conclusion:
These results show that a DNA vaccine encoding 
epitopes from melanoma antigens can induce 
measurable T-cell responses and, furthermore, 
it may confer protection from recurrence of 
melanoma with little associated toxicity. SCIB1 
deserves further evaluation as an adjuvant 
therapy.
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Using TCR gene modified T cells for adoptive cell 
transfer has been shown to have clinical success 
in treating melanoma and other malignancies. 
One of the challenges in using TCR gene 
modified T cells include proper expression of the 
introduced TCR and function. Mispairing between 
endogenous and introduced TCR chains allows 
for the potential of unanticipated off-target 
reactivity, autoimmunity, and impaired therapeutic 
efficacy against targeted antigens. One 
approach to improve TCR expression, pairing, 
and T cell function involves the modification of 
the introduced TCR genes to promote proper 
pairing. Some of these modifications include 
introducing a disulfide bridge in the alpha/beta 
constant regions, murine constant regions, codon 
optimization, TCR chain leucine zipper fusions, 
and a single chain TCR. We have previously 
cloned a novel TCR from a HLA-A2 restricted, 
HCV NS3:1406-1415-reactive T cell clone. We 
have developed a surface transduction marker, 
CD34t, that allows for measurement of TCR 
expression due to the 1:1 stoichiometric ratio 
between CD34t and TCR proteins. Our results 
revealed that the murinized Cβ2 TCR and the 
leucine zipper TCR have the highest levels 
of expression per transduced T cells when 
compared to the wild type TCR. It is evident that 
while some modifications have higher levels of 
TCR expression, this does not always result in 
increased function. Although, on a transduced 
